Oral carbidopa has no effect on the renal response to angiotensin II in normal man.
1. The effect of inhibition of intrarenal dopamine synthesis by carbidopa on the renal response to angiotensin II infusion was studied in six healthy salt-loaded volunteers. 2. Subjects received an infusion of angiotensin II at two doses (0.5 and 1.0 ng min-1 kg-1) on two occasions. Before one study they took a single dose of carbidopa (100 mg) by mouth. 3. The plasma concentrations of angiotensin II produced by the infusion were similar on both study days. Angiotensin II infusion reduced urinary dopamine excretion on the control day. Urinary dopamine excretion was undetectable at all times after carbidopa, but carbidopa did not change the basal excretion rate of sodium. Despite inhibition of renal dopamine synthesis, the reductions in both absolute and fractional sodium excretion during the angiotensin II infusion were not different from those seen in the control study. 4. The reductions in glomerular filtration rate and effective renal plasma flow which occurred during angiotensin II infusion were not modified by pretreatment with carbidopa. 5. The renal response to angiotensin II is not modulated either wholly or in part by endogenous intrarenal dopamine levels. The fall in urinary dopamine excretion which occurs during angiotensin II infusion is consistent with a modulatory role for tubular reabsorptive capacity in the regulation of proximal tubular dopamine synthesis.
Eadington
D W
DW
Department of Medicine, Royal Infirmary, Edinburgh, U.K.
Swainson
C P
CP
Lee
M R
MR
D000328:Adult; D000804:Angiotensin II / Q000494:pharmacology*; D002230:Carbidopa / Q000494:pharmacology*; D004298:Dopamine / Q000652:urine*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000098:blood supply / Q000187:drug effects*; D008297:Male; D012039:Regional Blood Flow / Q000187:drug effects; D012964:Sodium / Q000652:urine
D000804:Angiotensin II; D012964:Sodium; D002230:Carbidopa; D004298:Dopamine